Lorigerlimab for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma in Patients with Homologous Recombination Deficiency
This phase II trial studies how well lorigerlimab works in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread from where it first started (primary site) to other places in the body (metastatic) and that has changes (mutations) in the BRCA1, BRCA2, PALB2, RAD51C, and RAD51D genes (homologous recombination deficiency). Immunotherapy with monoclonal antibodies, such as lorigerlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Inclusion Criteria
- Albumin ≥ 3.0 g/dL (within 14 days of cycle 1 day 1)
- Neutrophils > 1000/μL (stable off any growth factor within 4 weeks of first study treatment administration) (within 14 days of cycle 1 day 1)
- Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures
- Must have prior exposure and disease progression after at least one line of platinum-based chemotherapy. Platinum-based chemotherapy given in the neo-adjuvant or adjuvant setting also satisfies this requirement if progression occurs within 1 year of the end of adjuvant therapy
- Measurable disease on baseline imaging by CT (or MRI where CT is contraindicated) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Prior receipt of a PARP inhibitor is allowed but not mandatory
- Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) < 3.0 × ULN or < 5.0 x ULN if liver metastases are present (within 14 days of cycle 1 day 1)
- Serum creatinine < 1.5 × upper limit of normal (ULN), or creatinine clearance ≥ 30 mL/min (measured or calculated using Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration Formula [CKD-Epi]) (within 14 days of cycle 1 day 1)
- Hemoglobin > 8.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration) (within 14 days of cycle 1 day 1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Female patients of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first dose of study medication) with repeat urine or serum pregnancy test of day 1 of each cycle and at the end of treatment visit. Non-childbearing potential is defined as: a. ≥ 50 years of age and has not had menses for greater than 1 year. b. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation. c. Status is post hysterectomy, bilateral oophorectomy, or tubal ligation. d. Female patients who are diagnosed with a tumor that is known to secrete human chorionic gonadotropin (HCG) must be certified not pregnant based on clinical evidence and investigator judgment
- Total bilirubin < 1.5 × ULN (except patients with Gilbert syndrome who must have a total bilirubin level of < 3.0 × ULN) (within 14 days of cycle 1 day 1)
- Must have an accessible tumor amenable to a safe biopsy where the major complication rate is ≤ 1.5% in the judgement of the investigator
- Female patients of child-bearing potential must agree to use highly effective contraceptive measures starting with the screening visit through 7 months after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient
- Histologically confirmed pancreas carcinoma with metastatic disease. Neuroendocrine neoplasms are not eligible. Adenosquamous, squamous and acinar histologies are allowed provided criteria is fulfilled, and these histologies comprise no more than 10% of the total accrual
- ≥ 18 years of age
- Life expectancy of at least 3 months
- Documented germline mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D that is known or predicted to be detrimental or lead to loss of function on a Clinical Laboratory Improvement Act (CLIA)-approved assay (e.g. Invitae, Ambry, Myriad, Tempus)
- Willing and able to comply with the requirements of the protocol
- Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 7 months after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient
- Platelets > 100 × 10^3/μL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration) (within 14 days of cycle 1 day 1)
Exclusion Criteria
- Patients with hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) is negative
- Known central nervous system (CNS) involvement as follows: a. Untreated CNS metastases. b. Leptomeningeal metastases. c. NOTE: Patients may be eligible if CNS metastases have been treated and patients have neurologically returned to baseline (except for residual signs and symptoms related to the CNS treatment)
- Active infection requiring treatment within 2 weeks of cycle 1 day 1
- Patients with hepatitis B virus (HBV) infection are eligible if hepatitis B surface antigen and HBV DNA are negative
- Note: All patients diagnosed with disease known to secrete HCG will test positive for pregnancy. Therefore, a positive pregnancy test is not exclusion criteria for these patients. However, pregnancy negative status must be otherwise reasonably ascertained by other objective means
- Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
- History of allogeneic solid organ or stem cell transplant
- Washout period prior to cycle 1 day1: Participants must recover from clinically significant adverse events from their more recent therapy or intervention prior to study enrollment. No specific time windows are given
- Clinically significant cardiovascular disease including but not limited to: * Myocardial infarction or unstable angina within 6 months prior to initiation of study treatment * Stroke or transient ischemic attack within 6 months prior to initiation of study treatment * Clinically significant cardiac arrhythmias * Uncontrolled hypertension: systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg * Congestive heart failure (New York Heart Association class III–IV) * Pericarditis or clinically significant pericardial effusion. Trace pericardial fluid is not exclusionary * Any history of myocarditis * Fridericia's formula corrected QT interval (QTcF) > 480 milliseconds. In the event that a single QTcF is > 480 milliseconds, the participant may enroll if the average QTcF for the 3 electrocardiograms (ECGs) is < 480 milliseconds * Baseline left ventricular ejection fraction (LVEF) of < 50% * Elevated troponin I (or troponin T) (> ULN) at screening. A repeat troponin assessment during the screening period is permitted in consultation with the sponsor study physician. If repeat troponin assessment is normal, the participant may be eligible for enrollment
- Participants with impaired decision-making capacity
- Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent), are permitted in the absence of active autoimmune disease
- Clinically significant gastrointestinal disorders including: * Any history of gastrointestinal perforation unless the affected area has been deemed by the investigator to no longer be a risk for perforation * History of clinically significant gastrointestinal bleeding within 4 weeks prior to initiation of study treatment * History of acute pancreatitis within 4 weeks prior to the initiation of study treatment * Diverticulitis that is clinically significant in the opinion of the investigator based on the extent or severity of known disease and/or the occurrence of clinically significant disease flares within 4 weeks prior to the initiation of study treatment administration * Bowel obstruction or impending bowel obstruction within the past 3 months
- Has clinically significant ascites defined as requiring 1 or more therapeutic paracenteses in the last 4 weeks prior to study entry
- History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient’s participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of study treatment (i.e. patients with a history of prior malignancy are eligible if treatment was completed at least 1 year before the first dose of study treatment and the patient has no evidence of disease). Patients with history of prior early-stage basal/squamous cell skin cancer or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible
- Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e. with use of disease modifying agents or immunosuppressive drugs). Replacement therapy with thyroxine, insulin or physiologic corticosteroid replacement therapy is not considered systemic treatment for autoimmune disease
- Active hepatitis B or C infection
- Grade 2 or higher peripheral neuropathy
- Has received any prior therapy with an anti-PD-1/PD-L1 antibody or an anti-CTLA-4 antibody
- Breastfeeding patients
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- Symptomatic interstitial lung disease (ILD) or ILD which may interfere with detection and management of new immune-related pulmonary toxicity
- HIV positive, except CD4 > 200 and HIV viral load undetectable
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07565155.
Locations matching your search criteria
United States
Florida
Miami
PRIMARY OBJECTIVE:
I. To determine the overall response rate (ORR) to lorigerlimab in patients with refractory PDAC and pathogenic germline variants (PGV's) in BRCA1/2, PALB2 and RAD51C/D.
SECONDARY OBJECTIVE:
I. To determine the progression-free survival (PFS) and overall survival (OS) with lorigerlimab treatment in this population.
EXPLORATORY OBJECTIVES:
I. Identification of transcriptional programs in pretreatment tumor biopsies associated with response.
II. Identification of changes in circulating immune cell populations in response to treatment based on flow cytometric analysis and T cell receptor repertoire in blood samples.
III. Identification of changes in circulating tumor deoxyribonucleic acid (DNA) levels in response to therapy and its association with response.
OUTLINE:
Patients receive lorigerlimab intravenously (IV) over 1-2 hours on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo echocardiography (ECHO) and tissue biopsy during screening. Patients also undergo blood sample collection and computed tomography (CT), fludeoxyglucose (FDG) positron emission tomography (PET)-CT, or magnetic resonance imaging (MRI) plus CT throughout the study.
After completion of study treatment, patients are followed up at 28 and 90 days and then every 3 months for up to 2 years.
Trial PhasePhase II
Trial Typetreatment
Lead OrganizationUniversity of Miami Miller School of Medicine-Sylvester Cancer Center
Principal InvestigatorPeter Joel Hosein
- Primary ID20251062
- Secondary IDsNCI-2026-08292
- ClinicalTrials.gov IDNCT07565155